Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment

Biochemical Pharmacology

Volumn 73, Issue 7, 2007, Pages 990-1000

  Huang, Canhua ^a   Ida, Hiroshi ^b   Ito, Kosei ^a,b   Zhang, Haiyuan ^a   Ito, Yoshiaki ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Chemotherapy; Gastric cancer; RUNX3; Vorinostat

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR RUNX3; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RUNX3 GENE; STOMACH CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 3 SUBUNIT; GENE EXPRESSION REGULATION; HISTONES; HUMANS; HYDROXAMIC ACIDS; STOMACH NEOPLASMS;

EID: 33847228395     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.12.013     Document Type: Article

References (40)

1. Jaenisch R., and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 (2003) 245-254
2. Kopelovich L., Crowell J.A., and Fay J.R. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 95 23 (2003) 1747-1757
3. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 3 (2001) 194-202
4. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
5. Yoshida M., Shimazu T., and Matsuyama A. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog Cell Cycle Res 5 (2003) 269-278
6. Curtin M., and Glaser K. Histone deacetylase inhibitors: the Abbott experience. Curr Med Chem 10 22 (2003) 2373-2392
7. Delorme B.A. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem 10 22 (2003) 2359-2372
8. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 91 (2004) 137-168
9. Remiszewski S. The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 10 22 (2003) 2393-2402
10. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23 24 (2004) 4198-4208
11. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89 (1997) 765-771
12. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109 1 (2002) 113-124
13. Ito K., Liu Q., Salto-Tellez M., Yano T., Tada K., Ida H., et al. RUNX3, a novel tumor suppressor, is highly inactivated in gastric cancer by protein mislocalization. Cancer Res 65 (2005) 7743-7750
14. Chi X.Z., Yang J.O., Lee K.Y., Ito K., Sakakura C., Li Q.L., et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25 18 (2005) 8097-8107
15. Lau Q.C., Raja E., Salto-Tellez M., Liu Q., Ito K., Inoue M., et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66 13 (2006) 6512-6520
16. Imamura Y., Hibi K., Koike M., Fujiwara M., Kodera Y., Ito K., et al. RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res 25 4 (2005) 2627-2630
17. Sato K., Tomizawa Y., Iijima H., Saito R., Ishizuka T., Nakajima T., et al. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 15 1 (2006) 129-135
18. Park W.S., Cho Y.G., Kim C.J., Song J.H., Lee Y.S., Kim S.Y., et al. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med 37 4 (2005) 276-281
19. Kang G.H., Lee S., Lee H.J., and Hwang K.S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 202 2 (2004) 233-240
20. Ruefli A.A., Smyth S.M., and Johnstone R.W. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 95 7 (2000) 2378-2385
21. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gen Express 5 (1996) 245-253
22. Richon V.M., Zhou X., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 27 (2001) 260-264
23. Romanski A., Bacic B., Bug G., Preifer H., Gul H., Remiszewski S., et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89 (2004) 419-426
24. Kagoshima H., Akamatsu Y., Ito Y., and Shigesada K. Functional dissection of the α and β subunits of transcription factor PEBP2 and the Redox susceptibility of Its DNA binding activity. J Biol Chem 20;271 51 (1996) 33074-33082
25. Rountree M.R., Bachman K.E., Herman J.G., and Baylin S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 20 24 (2001) 3156-3165
26. Bachman K.E., Rountree M.R., and Baylin S.B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem 276 34 (2001) 32282-32287
27. Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., and Wolffe A.P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25 (2000) 338-342
28. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 1 (1999) 103-107
29. Primeau M., Gagnon J., and Momparler R.L. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103 2 (2003) 177-184
30. Ito Y., and Miyazono K. RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 13 (2003) 43-47
31. INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994) 257-261
32. Reynisdottir I., Polyak K., Iavarone A., and Massague J. Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9 (1995) 1831-1845
33. Koeller K.M., Haggarty S.J., Perkins B.D., Leykin L., Wong J.C., Kao M.C., et al. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol 10 5 (2003) 397-410
34. Kim J.S., Lee S., Lee T., Trepel J.B., and Lee Y.-W. Transcriptional activation of p21WAF1/CIP1 by Apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 281 (2001) 866-871
35. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 10 (2005) 3697-3702
36. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98 19 (2001) 10833-10838
37. Henderson C., Mizzau M., Paroni G., Maestro R., Schneider C., and Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278 14 (2003) 12579-12589
38. Yano T., Ito K., Fukamachi H., Chi X.Z., Wee H.J., Inoue K., et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 26 12 (2006) 4474-4488
39. Yamamura Y., Lee W.L., Inoue K., Ida H., and Ito Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281 8 (2006) 5267-5276
40. Cohen L.A., Amin S., Marks P.A., Rifkind R.A., Desai D., and Richon V.M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 19 6B (1999) 4999-5005